Teva, Antares Receives FDA Approval For Needle-Free Injector
First product approval stemming from portfolio of product collaborations batween Teva and Antares
Teva and its partner, Antares have received approval of a Supplemental New Drug Application (sNDA), which added needle-free injection to its Tev-Tropin, human growth hormone (hGH) drug label.
Teva would market the Antares needle-free injector as the Tev-Tropin Tjet Injector system.
Larry Downey, Head of North America Brand Pharmaceuticals division at Teva, said: We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares and to offer patients a less invasive delivery system.”
Paul Wotton, President and CEO of Antares, said: This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the company. We look forward to the launch of this product by Teva.
Related Insight
Suppliers Directory
ENNOV - Medical Device and Drug Development Compliance Specialists
ENNOV INC. (Ennov) provides Ennov5 "Business Suite Solutions" to enable companies to obtain and maintain regulatory compliance while focusing their attention on the business of maximizing profitability by leveraging computing technology.
Suppliers
Peptide Specialty Laboratories - Peptide Synthesis and Antibody Preparation.
Peptide Specialty Laboratories (PSL) GmbH was founded in September 2000. The company is located within the Technology Park in Heidelberg, Germany. PSL is a spin off of the German Cancer Research Center (DKFZ) in Heidelberg, where the cofounder and manager of the company, Dr. H.-R. Rackwitz has gained a long time of experience in peptide synthesis and antibody preparation.
Suppliers
Biognosys - Targeted Proteomics Research Solutions & Tools
Biognosys is a Swiss proteomics company dedicated to the development of targeted proteomics services and tools. We use scheduled multiple reaction monitoring (MRM) to measure and quantify proteins from any species in any biological matrix. Our patented technology allows us to develop and validate MRM assays for new protein targets within 4 to 6 weeks with unprecedented efficiency. This approach not only accelerates biomarker or drug target discovery but also enables high-throughput protein measurement of drug response in complex samples.
Suppliers
ADAPT Localization - The Translation and Localization Specialists
ADAPT Localization Services provides the full range of translation and localization for the Life Sciences, Medical and IT industries.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
A Guide to OEE - Overall Equipment Effectiveness
Published by Garvens
White Papers
Transforming Randomization and Trial Supply Management
Published by Medidata Solutions
White Papers
Tips & Tricks - GPC/SEC: Absolute or True Molar MAsses for MAcromolecules - Mass Spectrometry as a New Solution
Published by Polymer Standards Service
White Papers
Plastic Volumetric Flasks and Reagent Bottles Now Also With Light Protection
Published by VITLAB®
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.